Table 1.
Baseline patient characteristics
| Characteristic | n = 146 |
|---|---|
| Median age, years (range) | 54 (17–78) |
| Sex (female/male) [n (%)] | 70 (48)/76 (52) |
| ECOG PS [n (%)] | |
| 0 | 85 (58) |
| 1 | 57 (39) |
| 2 | 4 (3) |
| Time from diagnosis, months (range) | 39 (4–260) |
| Patients with liver metastases [n (%)] | 55 (38) |
| Patients with ocular melanoma [n (%)] | 1 (1) |
| Patients with mucosal melanoma [n (%)] | 5 (3) |
| Elevated LDH (>480 IU/L) [n (%)]a | 52 (45) |
| Number of previous therapies | |
| 1 | 79 (54) |
| 2 | 47 (32) |
| ≥3 | 20 (14) |
| Previous therapy [n (%)] | |
| Dacarbazine | 52 (36) |
| Fotemustine | 59 (40) |
| Temozolomide | 79 (54) |
| Platinum-based chemotherapy | 54 (37) |
| Interferon | 20 (14) |
| BRAF inhibitor | 22 (15) |
| Received prior radiotherapy for brain metastasis [n (%)] | 6 (4) |
ECOG Eastern Cooperative Oncology Group, LDH lactate dehydrogenase, PS performance status
aOut of 115 patients evaluated for LDH levels